Loading patent…
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsHiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
Estimating the term…
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
1-21. (canceled)
A method of treating Parkinson's disease and/or L-DOPA motor complications, comprising administering an effective amount of at least one adenosine A2A receptor antagonist in combination with at least one member selected from the group consisting of a COMT inhibitor, a DA and an MAO inhibitor to a patient in need thereof.
A composition for the treatment of Parkinson's disease comprising an effective amount of at least one adenosine A2A receptor antagonist, and at least one member selected from the group consisting of a COMT inhibitor, a DA and an MAO inhibitor.
A method of prolonging effective treatment of Parkinson's disease comprising administering to a patient in need thereof either an adenosine A2A receptor antagonist, or a combination of an adenosine A2A receptor antagonist and a dopamine agonist, in an amount effective to delay or remove the patient's need for add-on L-DOPA therapy.
43-50. (canceled)
Dependencies are inferred from the claim text.